StroMel (Autologous mesenchymal stem cells) / Akan Bio - LARVOL DELTA

Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: Akan Biosciences, LLC | Trial completion date: Dec 2022 ➔ Aug 2027 | Trial primary completion date: Dec 2022 ➔ Aug 2027

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Safety and Tolerability of StroMel™ in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: Akan Biosciences, LLC | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Akan Biosciences Announces FDA Acceptance of IND Application for StroMel in Osteoarthritis of Knee (PRNewswire) - "Akan Biosciences...today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for StroMel™, its lead candidate for the treatment of Osteoarthritis of Knee...The clinical trial is scheduled to initiate in March 2021."

IND • Trial initiation date • Osteoarthritis • Pain